- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02599480
Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure (Beta3_LVH)
A Multi-centre Randomized, Placebo-controlled Trial of Mirabegron, a New beta3-adrenergic Receptor Agonist on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease
This study will assess the efficacy of mirabegron, a new beta3-adrenergic receptor in the prevention of heart failure. This is a two armed, prospective, randomized, placebo-controlled, multi-centric european phase IIb trial with placebo and mirabegron distributed in a 1:1 fashion. The patients enrolled will have cardiac structural remodeling with or without symptoms of heart failure (maximum NYHA II).
Patients will be monitored for change in left ventricular mass (assessed by cardiac MRI) and/or changes in diastolic function (assessed by echocardiography) after 12 months of treatment.
Study Overview
Status
Conditions
Detailed Description
Background Heart failure (HF) represents a major and growing public health burden. Patients with HF are classically divided into two groups: those with HF with preserved ejection fraction (HFpEF), and those with HF and reduced ejection fraction (HFrEF). As HF is a progressive disorder increasing with age, the proportion of these patients is rising due to the aging of the population. Beside costs, HFpEF also puts a heavy burden on the quality of life of (mostly elderly) patients, with a loss of autonomy and the dyscomfort of repeated hospitalisations. Therefore, HFpEF is a chronic, costly, debilitating disease.
A major contributor to HFpEF is myocardial remodelling, e.g. hypertrophy and fibrosis, as well as cellular functional/structural modifications leading to alteration in contractile properties and ventricular distensibility. Unfortunately, there are currently no evidence-based treatment strategies.
Study claim The proposed clinical trial will provide a proof of concept in humans for the clinical efficacy of a novel therapeutic concept: β3AR activation to attenuate/prevent cardiac remodeling. Recently, a new, specific agonist at human β3-AR (mirabegron) with higher benefit/risk balance was developed and marketed for clinical use in a non-cardiovascular disease (overactive bladder disease). The trial will test the drug repurposing of mirabegron for the prevention of cardiac remodeling leading to HFpEF.
Using pre-clinical models, the investigators demonstrated that activation of β3AR attenuates myocardial hypertrophy and fibrosis in response to neurohormonal or hemodynamic stresses, without compromising LV function. Therefore, the recent availability of this new drug offers the possibility to test the potential benefit of mirabegron (vs placebo) as add-on therapy (on top of standard care) to prevent/delay myocardial remodelling in patients at high risk of developing HFpEF.
Who can participate? Patients with structural cardiac disease with or without HF symptoms (max. NYHA 2).
What does the study involve? Patients will be requested to go 5 times to the hospital to perform cardiac MRI (3X), echocardiography (3X), exercise tolerance test (2X), Pet scanning (2X) and blood sampling (4X).
Who is the sponsor? The Université catholique de Louvain (UCL) is the academic sponsor and Prof. Jean-Luc Balligand is the principal coordinator of the study.
Who is funding the study? Beta3_LVH is an investigator-initiated project funded by a Horizon 2020 grant from the European Commission.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1200
- Cliniques Universitaires Saint-Luc
-
-
-
-
-
Nantes, France, 44000
- Nantes university hospital (CHU Nantes)
-
-
-
-
-
Berlin, Germany, 10115
- Center for Cardiovascular Research Berlin (CCR/Charité)
-
Göttingen, Germany, 37099
- University Medical Center Göttingen (UMG-GOE)
-
-
-
-
-
Athens, Greece, 115 27
- Athens University Medical School (NKUA)
-
-
-
-
-
Bergamo, Italy, 1 - 24127
- Hospital "Papa Giovanni XXIII" (HPG23)
-
-
-
-
-
Wroclaw, Poland, 50-981
- Department of Heart Diseases at Wroclaw Medical University (UMW)
-
-
-
-
-
Lisbon, Portugal, 1649-028
- Association for Research and Development of the Faculty of Medicine (AIDFM)
-
-
-
-
-
Oxford, United Kingdom, OX3 9DU
- University of Oxford - Division of Cardiovascular Medicine (UOXF)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 90 years
- Arterial hypertension on stable therapy according to current guideline algorithms (including stable medication for at least four weeks before inclusion),
- Morphological signs of structural cardiac remodelling by echocardiography, i.e. increased LV mass index (110 g/m2 or higher for female; 134 g/m2 or higher for male subjects (Devereux, Reichek 1977)) or end-diastolic wall thickness >13 mm in at least one wall segment
- Patients may have atrial fibrillation (AF), but with well-regulated ventricular response, i.e. heart rate<100/min (RACE II - (Groenveld et al. 2013, 2013)),
- Written informed consent
- For subjects unable to read and/or write, oral informed consent observed by an independent witness is acceptable if the subject has fully understood oral information given by the Investigator. The witness should sign the consent form on behalf of the subject.
Exclusion Criteria:
- Unstable hypertension with systolic BP≥160 mm Hg and/or diastolic BP≥100 mm Hg (based on office measurement, not ambulatory measurement)
- Documented ischemic cardiac disease
- History of hospitalization for overt heart failure within last 12 months
- Patients after heart transplantation
- Genetic hypertrophic or dilated cardiomyopathy
- Dysthyroidism.
- Severe valvulopathy
- NYHA-class > II
- BMI >40 kg/m2
- EF < 50%, regardless of symptoms
- Known other cause (i.e. COPD) of respiratory dysfunction; patients under positive pressure (CPAP) treatment for sleep apnea syndrome may be included, provided they have been under regular treatment for at least one year before inclusion in the study
- eGFR < 30 ml/min (by MDRD formula)
- Abnormal liver function tests
- Type I diabetes, complicated type II diabetes
- Patients with anemia
- Patients with bladder outlet obstruction
- Patients using antimuscarinic cholinergic drugs for treatment of OAB
- Current use of digitalis, bupranolol, propranolol, nebivolol
- Patients continuously treated with Sildenafil or other PDE5 inhibitors.
- Current use of antifungal azole derivatives (fluconazole, itraconazole, miconazole, posaconazole, voriconazole)
- Current treatment with mirabegron or indication for future treatment with mirabegron due to other indications
- Contraindication for MRI
- Pregnant or nursing women
- Participation in any other interventional trial
- Fertile women (within two years of their last menstruation) without appropriate contraceptive measures (hormonal implant, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial (participants using a hormone-based method have to be informed of possible effects from the trial medication on contraception)
- Contraindication to mirabegron (e.g. hypersensitivity) or any other components of the trial medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: mirabegron
Patients will be orally administererd with 50 mg of mirabegron once a day during 12 months.
|
50 mg daily during 12 months
Other Names:
Echocardiography
Cardiac MRI
Maximal exercise capacity
Blood sampling for study assessments and future exploratory studies.
EndoPAT assessment
PET scanning for beige/brown fat activation
|
Placebo Comparator: Placebo
Patients will be orally administererd with a placebo once a day during 12 months.
|
Echocardiography
Cardiac MRI
Maximal exercise capacity
Blood sampling for study assessments and future exploratory studies.
EndoPAT assessment
PET scanning for beige/brown fat activation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in left ventricular mass index (LVMI)
Time Frame: 12 months
|
Change in left ventricular mass index (LVMI in g/m2, defined as left ventricular mass divided by body surface) measured at baseline and 12 months after randomisation.
|
12 months
|
Change in diastolic function
Time Frame: 12 months
|
Change in diastolic function, assessed as the ratio of peak early transmitral ventricular filling velocity to early diastolic tissue Doppler velocity (E/e') measured at baseline and 12 months after randomisation.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiac fibrosis
Time Frame: 12 months
|
Cardiac fibrosis at baseline and at 12 months.
Fibrosis is a key pathogenic mechanism of diastolic dysfunction, which is at the origin of HFpEF
|
12 months
|
Left atrial volume index
Time Frame: 12 months
|
Left atrial volume index at baseline and at 12 months.
This parameter determines diastolic filling (and was shown to predict treatment efficacy in HFpEF in the J-DHF trial (Yamamoto et al. 2013))
|
12 months
|
LV mass index (by cardiac MRI)
Time Frame: 6 months
|
LV mass index (by cardiac MRI) at 6 months,
|
6 months
|
Diastolic function (E/e')
Time Frame: 6 months
|
Diastolic function (E/e') at 6 months
|
6 months
|
serum biomarkers
Time Frame: 3, 6, 12 months
|
serum biomarkers (Galectin3, GDF15, NT-proBNP, hsTnT)
|
3, 6, 12 months
|
metabolic parameters
Time Frame: 3, 6, 12 months
|
metabolic parameters (fasting glucose, modified HOMA test, HbA1c, serum lipids)
|
3, 6, 12 months
|
Maximal exercise capacity
Time Frame: 12 months
|
Maximal exercise capacity (peak VO2) at baseline and 12 months.
|
12 months
|
Emergence of treatment-related adverse events
Time Frame: 12 months
|
Incidence of Treatment-Emergent Adverse Events
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Belge C, Hammond J, Dubois-Deruy E, Manoury B, Hamelet J, Beauloye C, Markl A, Pouleur AC, Bertrand L, Esfahani H, Jnaoui K, Gotz KR, Nikolaev VO, Vanderper A, Herijgers P, Lobysheva I, Iaccarino G, Hilfiker-Kleiner D, Tavernier G, Langin D, Dessy C, Balligand JL. Enhanced expression of beta3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation. 2014 Jan 28;129(4):451-62. doi: 10.1161/CIRCULATIONAHA.113.004940. Epub 2013 Nov 4.
- Balligand JL. beta(3)-Adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade "Stop or Encore?". J Am Coll Cardiol. 2009 Apr 28;53(17):1539-42. doi: 10.1016/j.jacc.2009.01.048. No abstract available.
- Dessy C, Balligand JL. Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol. 2010;59:135-63. doi: 10.1016/S1054-3589(10)59005-7.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Pathological Conditions, Anatomical
- Cardiomegaly
- Hypertrophy
- Hypertrophy, Left Ventricular
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Adrenergic Agonists
- Adrenergic beta-Agonists
- Adrenergic beta-3 Receptor Agonists
- Mirabegron
Other Study ID Numbers
- Beta3_LVH V1.0
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertrophy, Left Ventricular
-
Nagoya UniversityUnknownHypertensive Left Ventricular HypertrophyJapan
-
University of LeipzigCompletedLeft Ventricular Hypertrophy | Left Ventricular Failure | Left Ventricular Non-compaction CardiomyopathyGermany
-
Tulane UniversityJohns Hopkins UniversityRecruitingEndothelial Dysfunction | Vascular Stiffness | Left Ventricular Dysfunction | Left Ventricular HypertrophyUnited States
-
Assistance Publique - Hôpitaux de ParisInstitute of Cardiometabolism and Nutrition, FranceNot yet recruitingLeft Ventricular HypertrophyFrance
-
Instituto de Urologia e NefrologiaUnknownLeft Ventricular HypertrophyBrazil
-
Yale UniversityRecruitingLeft Ventricular HypertrophyUnited States
-
Cardiovascular Academy Society, TurkeyCompletedLeft Ventricular HypertrophyTurkey
-
University of California, San FranciscoTerminatedLeft Ventricular HypertrophyUnited States
-
Ege UniversityFresenius Medical Care North AmericaCompletedLeft Ventricular HypertrophyTurkey
-
Organon and CoCompletedHypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)
Clinical Trials on mirabegron
-
The Affiliated Ganzhou Hospital of Nanchang UniversityActive, not recruiting
-
Astellas Pharma IncCompletedHealthy Subjects | Plasma Concentration of MirabegronJapan
-
Thomas Jefferson UniversityAstellas Pharma IncTerminatedAchalasiaUnited States
-
Astellas Pharma IncCompletedHealthy Subjects | Bioavailability | Pharmacokinetics of MirabegronNetherlands
-
Cedars-Sinai Medical CenterRecruitingSyncope | Postural Orthostatic Tachycardia Syndrome | Chronic Orthostatic IntoleranceUnited States
-
Far Eastern Memorial HospitalRecruitingOveractive Bladder SyndromeTaiwan
-
Far Eastern Memorial HospitalRecruitingFemale Patients With Overactive Bladder SyndromeTaiwan
-
Astellas Pharma Europe Ltd.CompletedUrologic Diseases | Urinary Bladder Diseases | Urinary Bladder OveractiveUnited States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
-
Peking Union Medical College HospitalNot yet recruiting
-
Astellas Pharma Europe B.V.Completed